Guidelines on the management of Paget's disease of bone (Q39403135)

11 September 2017

Guidelines on the management of Paget's disease of bone (English)

1 reference

11 September 2017

P L Selby

1

1 reference

11 September 2017

M W J Davie

2

1 reference

11 September 2017

S H Ralston

3

1 reference

11 September 2017

M D Stone

4

1 reference

11 September 2017

Bone and Tooth Society of Great Britain

5

1 reference

11 September 2017

National Association for the Relief of Paget's Disease

6

1 reference

11 September 2017

1 September 2002

1 reference

11 September 2017

1 reference

11 September 2017

31

1 reference

11 September 2017

3

1 reference

11 September 2017

366-373

1 reference

The acute-phase response after bisphosphonate administration

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Effects of two oral doses of alendronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Mineralisation defects with pamidronate therapy for Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Mithramycin in Paget's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Prevalence of pelvic Paget's disease of bone in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans)

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Relapse of osteoporosis circumscripta as a lytic ring after treatment of Paget's disease with intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Pamidronate and Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Hypercalcaemia in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Recurrent hypercalcaemia in a young man with mono-ostotic Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Paget's disease of bone in 14 British towns

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Femoral fractures in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Outcome after fractures of the femur in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Improvement of pagetic bone lesions with risedronate treatment: a radiologic study.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Paget's disease of the orbit: before and after APD.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Diphosphonate Therapy of Paget's Disease of Bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Intravenous etidronate for spinal cord dysfunction due to Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Neurologic disturbances in Paget disease of bone: Response to calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Control of osteitis deformans using glucagon, calcitonin, and mithramycin

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

The epidemiology of Paget's disease in Britain: is the prevalence decreasing?

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Evidence for secular change in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

High-dose pamidronate in the management of resistant Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

The management of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Clinical experience with the use of two diphosphonates in the treatment of Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Radiological assessment of Paget's disease of bone after treatment with the bisphosphonates EHDP and APD.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Paget's disease: improvement of spinal cord dysfunction with diphosphonates and calcitonin.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Biochemical markers of bone turnover in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Hypercalcaemia due to immobilisation in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Side-effects of synthetic salmon and human calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Uveitis associated with pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Paget's disease of bone and quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Factors associated with self-rated health in patients with Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Short-term therapy with oral olpadronate in active Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Ibandronate treatment in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Spinal cord compression in Paget's disease of bone with reference to sarcomatous degeneration and calcitonin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

The role of mithramycin in the management of paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Spinal-cord syndrome due to non-compressive Paget's disease of bone: a spinal-artery steal phenomenon reversible with calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Paget's disease of bone: diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Severe orthopaedic complications of Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Treatment of Paget disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Alendronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Stabilization of hearing loss in Paget's disease with calcitonin and etidronate.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

A comparison of radiography and radioisotope scanning in the detection of Paget's disease and in the assessment of response to human calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

The Ilizarov external fixator for treatment of deformities in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Pamidronate disodium and possible ocular adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Successful treatment of resistant Paget's disease of bone with pamidronate.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Efficacy of the bisphosphonate APD in the control of Paget's bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Hypercalcaemia due to immobilization of a patient with Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Paget's disease of bone and hyperparathyroidism: coincidence or causal relationship?

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease--a double-blind randomized clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Long term effectiveness of low dose mithramycin for paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Diphosphonates in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Treatment of Paget's disease by weekly infusions of 3-aminohydroxypropylidene-1,1-bisphosphonate (APD)

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Mithramycin and long remission of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Mithramycin in Paget's disease of bone.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Paget's disease with spinal cord compression. Favourable course after decompression and calcitonin treatment in two cases

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Pamidronate in the treatment of Paget's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Goals of treatment for Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Charnley low-friction arthroplasty for Paget's disease of the hip

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Effect of calcitonin treatment on deafness due to Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD)

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Paget's disease of bone treated in five days with AHPrBP (APD) per Os

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Quantitative bone scintigraphy in Paget's disease treated with APD

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Treatment of Paget's disease of bone with single dose intravenous pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Lumbar spinal canal stenosis in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Long- and short-term side effects and safety of calcitonin in man: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Single-dose intravenous pamidronate is effective alternative therapy for Paget's disease refractory to calcitonin.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2802%2900817-7

7 January 2021

10.1016/S8756-3282(02)00817-7

Identifiers

DOI

1 reference

11 September 2017

1 reference